Truxal 15 mg Norveška - norveški - Statens legemiddelverk

truxal 15 mg

h. lundbeck a/s - klorprotiksenhydroklorid - tablett, filmdrasjert - 15 mg

Truxal 25 mg Norveška - norveški - Statens legemiddelverk

truxal 25 mg

h. lundbeck a/s - klorprotiksenhydroklorid - tablett, filmdrasjert - 25 mg

Truxal 50 mg Norveška - norveški - Statens legemiddelverk

truxal 50 mg

h. lundbeck a/s - klorprotiksenhydroklorid - tablett, filmdrasjert - 50 mg

Zyvoxid 600 mg Norveška - norveški - Statens legemiddelverk

zyvoxid 600 mg

pfizer as - linezolid - tablett, filmdrasjert - 600 mg

Linezolid Krka 600 mg Norveška - norveški - Statens legemiddelverk

linezolid krka 600 mg

krka, d.d. novo mesto - linezolid - tablett, filmdrasjert - 600 mg

Linezolid Accord 2 mg/ ml Norveška - norveški - Statens legemiddelverk

linezolid accord 2 mg/ ml

accord healthcare b.v. - linezolid - infusjonsvæske, oppløsning - 2 mg/ ml

Copiktra Europska Unija - norveški - EMA (European Medicines Agency)

copiktra

secura bio limited - duvelisib - leukemia, lymphocytic, chronic, b-cell; lymphoma, follicular - antineoplastiske midler - copiktra monotherapy is indicated for the treatment of adult patients with: relapsed or refractory chronic lymphocytic leukaemia (cll) after at least two prior therapies.  follicular lymphoma (fl) that is refractory to at least two prior  systemic therapies.

Tukysa Europska Unija - norveški - EMA (European Medicines Agency)

tukysa

seagen b.v. - tucatinib - breast neoplasms; neoplasm metastasis - antineoplastiske midler - tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with her2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑her2 treatment regimens.

Efient Europska Unija - norveški - EMA (European Medicines Agency)

efient

substipharm - prasugrel - acute coronary syndrome; angina, unstable; myocardial infarction - antithrombotic agents - efient, co administreres med acetylsalisylsyre (asa), angis for forebygging av aterotrombotiske hendelser hos pasienter med akutt koronarsyndrom (jeg. ustabil angina, ikke-st-segmentet-elevation hjerteinfarkt [ua / nstemi] eller st-segmentet-elevation hjerteinfarkt [stemi]) under primær eller forsinket pci-behandling (pci).

Prasugrel Mylan Europska Unija - norveški - EMA (European Medicines Agency)

prasugrel mylan

mylan pharmaceuticals limited - prasugrel besilate - myocardial infarction; acute coronary syndrome; angina, unstable - antithrombotic agents - prasugrel mylan, co gis med acetylsalisylsyre (asa), er indikert for forebygging av atherothrombotic hendelser hos voksne pasienter med akutt koronar syndrom (i. ustabil angina, ikke-st-segmentet elevation myocardial infarction [ua/nstemi] eller st-segmentet elevation myocardial infarction [stemi]) gjennomgår primære eller forsinket perkutan koronar intervensjon (pci).